September 15, 2020 - Frequency Therapeutics presented results from a longer-term durability study of its acquired sensorineural hearing loss candidate, saying FX-322 showed significant improvement for some patients in key measures of hearing that were sustained for up to 21 months.

Pioneering RNA editing to deliver the future of medicine · RNA editing holds great promise to rewrite what’s possible for patients. Since the discovery of the first generation of editing technologies, researchers have been working to overcome the inherent complexity of these initial approaches ...

Twitter

As he says, “specifics around pricing and regulatory ‘really need to be managed and played out appropriately'” (in other words, NOT eagerly telling us “FX-322 WILL COST EXACTLY THESE MANY DOLLARS” while the drug is still in phase 2a clinical trials).

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

March 23, 2021 - FX-322 Phase 1b Study Confirms Hearing Improvement from Single Injection. Interim FX-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit.

322 CNY to USD - FX Currency Exchange Rate. #322CNY #CNY #USD #CNYUSD

April 11, 2018 - This is a phase 1 safety study performed in male or female adult participants with an established diagnosis of severe to profound sensorineural hearing loss tha...

September 6, 2019 - Source: https://www.sec.gov/Archives/edgar/data/1703647/000119312519239976/d72917ds1.htm Reddit thread: Frequency Therapeutics files IPO, first FX-322 results published! from tinnitus Credit: Thank you to Reddit user /u/pandoira for finding this update and bringing it to the attention of the ...

FX-322-208 is a Randomized, Placebo-Controlled Study to Evaluate Hearing Improvement in Subjects with Acquired SNHL Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclusion Criteria and Study Design LEXINGTON, Mass.

The Investor Relations website contains information about Frequency Therapeutics's business for stockholders, potential investors, and financial analysts.

May 24, 2022 - This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic i...

FX-322 in Adults With Age-Related Sensorineural Hearing Loss - Full Text View.

322 EUR to MXN - FX Currency Exchange Rate. #322EUR #EUR #MXN #EURMXN

Study record managers: refer to the Data Element Definitions if submitting registration or results information

322 VND to USD - FX Currency Exchange Rate. #322VND #VND #USD #VNDUSD

July 12, 2022 - Frequency Therapeutics’ hearing loss treatment FX-322 did not demonstrate improvements versus placebo a Phase IIa study finds.

Study record managers: refer to the Data Element Definitions if submitting registration or results information

Study record managers: refer to the Data Element Definitions if submitting registration or results information

Presbycusis, Hearing Loss, Sensorineural, Noise Induced Hearing Loss Trial in United States (FX-322, ) · Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss Trial in United States (FX-322, Placebo)